Answers are grounded in this paper and cite their sources.
Assesses urease inhibition by new oxidovanadium complexes in Helicobacter pylori, indicating potential therapeutic use.
In this work, four new oxidovanadium(V) complexes with the general formula [VOLL’] were prepared. L is the dianionic form of 2-hydroxy-5-methyl-N'-(3-methylbenzylidene)benzohydrazide (H2L1) for complexes 1 and 2, and 2-hydroxy-4-methoxy-N'-(3-methylbenzylidene)benzohydrazide (H2L2) for complexes 3 and 4. L’ is the deprotonated form of methyl maltol (HLa) for complexes 1 and 3, and ethyl maltol (HLb) for complexes 2 and 4. The structural features of the complexes were assigned using the single crystal X-ray diffraction and other physicochemical techniques. The V atoms in the complexes are in octahedral coordination. Inhibitory activities of the acylhydrazones and complexes were evaluated on Helicobacter pylori urease. All the complexes show effective activity with IC50 values of 15.3–27.2 μmol L–1.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: